BioVie Announces Topline Results from Phase 2 ADDRESS—LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patientsin pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post—exertional malaiseBezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall s…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.